Trials / Conditions / Pancreatic Adenocarcinoma Metastatic

Pancreatic Adenocarcinoma Metastatic

22 registered clinical trials studyying Pancreatic Adenocarcinoma Metastatic — 10 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Predictive Value of Transcriptome-based OncoTreat/Oncotarget and Organoid Testing in Metastatic Pancreatic Can NCT06615830	Prof. Dr. med. Dres. h.c. Jan Schmidt, MME	—
Recruiting	Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Ad NCT07491445	Revolution Medicines, Inc.	Phase 3
Not Yet Recruiting	NH002-mediated Sonoporation With Chemotherapy in Advanced Pancreatic Cancer NCT07314385	National Taiwan University Hospital	Phase 1
Recruiting	Clinical Trial of OMTX705 in Combination With Gemcitabine/Nab-Paclitaxel and Tislelizumab in Patients With Adv NCT07377045	Oncomatryx Biopharma S.L.	Phase 1
Recruiting	TTFields and Chemotherapy in Metastatic Pancreatic Adenocarcinoma (mPDAC) NCT07284277	Clinica Universidad de Navarra, Universidad de Navarra	Phase 1 / Phase 2
Recruiting	Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has NCT06747845	Abramson Cancer Center at Penn Medicine	Phase 2
Active Not Recruiting	The Seven Trial: Exploiting the Unfolded Protein Response NCT06076837	HonorHealth Research Institute	Phase 1
Recruiting	PD-1 Antibody and Sapropterin Dihydrochloride in Patients With PDAC NCT06396637	Sun Yat-sen University	Phase 2
Completed	Real World Efficacy, Safety of Nanoliposomal Irinotecan With Fluorouracil and Folinic Acid in Metastatic Pancr NCT06006728	University Hospital, Bordeaux	—
Recruiting	XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies. NCT06792435	Evopoint Biosciences Inc.	Phase 1 / Phase 2
Recruiting	Penpulimab Combined With Anlotinib and Nab-paclitaxel Plus Gemcitabine as First-line Treatment for Advanced Me NCT06051851	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	Phase 2
Active Not Recruiting	FOLFIRINOX + Elraglusib + Losartan In Pancreatic Cancer NCT05077800	Colin D. Weekes, M.D., PhD	Phase 2
Terminated	tailOred dRug repurposIng of dEcitabine in KRAS-dependeNt refracTory pAncreaTic cancEr NCT05360264	Luca Cardone	Phase 2
Recruiting	SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells NCT04150042	General Oncology, Inc.	Phase 1
Unknown	Efficacy Evaluation of Sequential Treatment With AG and Modified Folfirinox in Metastatic Pancreatic Adenocarc NCT03633734	Second Affiliated Hospital, School of Medicine, Zhejiang University	Phase 1 / Phase 2
Withdrawn	QUILT-2.022 NANT-008 in Combination w/ 5-fluorouracil, Bevacizumab, Leucovorin & Oxaliplatin in Subjects With NCT03127124	NantPharma, LLC	Phase 1 / Phase 2
Terminated	Cabozantinib and Erlotinib for Patients With EGFR and c-Met Co-expressing Metastatic Pancreatic Adenocarcinoma NCT03213626	Patrick Joseph Loehrer Sr.	Phase 2
Completed	To Assess the Safety of Continuous IV Administration of Plerixafor in Patients With Advanced Pancreatic, Ovari NCT02179970	CCTU- Cancer Theme	Phase 1
Completed	Efficacy and Safety of L-asparaginase Encapsulated in RBC Combined With Gemcitabine or FOLFOX in 2nd Line for NCT02195180	ERYtech Pharma	Phase 2
Completed	Scheduling Nab-paclitaxel With Gemcitabine NCT03529175	CCTU- Cancer Theme	Phase 2
Completed	Effect on Tumor Perfusion of a Chemotherapy Combining Gemcitabine and Nab-paclitaxel (Abraxane) in Pancreatic NCT01715142	Jean-Luc Van Laethem	EARLY_Phase 1
Completed	Open-Label Phase 2 Efficacy Trial of Cancer Macrobeads in Patients With Treatment-Resistant Pancreatic/Colorec NCT01053013	The Rogosin Institute	Phase 2